Cancer Letters
Volume 225, Issue 1 , Pages 75-83 , 8 July 2005

Experimental model of pulmonary metastasis treatment with IFNα

  • Cristina Martínez

      Affiliations

    • Department of Pathology, Faculty of Medicine, University of Murcia, 30100 Espinardo, Murcia, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 96 836 7150; fax: +34 96 836 4150.
    • ,
  • Vicente Vicente

      Affiliations

    • Department of Pathology, Faculty of Medicine, University of Murcia, 30100 Espinardo, Murcia, Spain
    • ,
  • Ma Josefa Yáñez

      Affiliations

    • Department of Pathology, Faculty of Medicine, University of Murcia, 30100 Espinardo, Murcia, Spain
    • ,
  • Juana Ma García

      Affiliations

    • Cell Culture Service, Faculty of Medicine, University of Murcia, 30100 Espinardo, Murcia, Spain
    • ,
  • Manuel Canteras

      Affiliations

    • Department of Biostatistics, Faculty of Medicine, University of Murcia, 30100 Espinardo, Murcia, Spain
    • ,
  • Miguel Alcaraz

      Affiliations

    • Department of Radiology and Physical Medicine, Faculty of Medicine, University of Murcia, 30100 Espinardo, Murcia, Spain

Received 26 July 2004 ,Revised 25 November 2004 ,Accepted 28 November 2004.

References 

  1. Serraino D, Frattino L, Ginni W, Campisi C, Pietropaolo M, Trimarco G, et al. Epidemiological aspects of cutaneous malignant melanoma (review). Oncol. Rep. 1998;5:905–909
  2. Linet MS. Evolution of cancer epidemiology. Epidemiol. Rev. 2000;22:35–56
  3. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J. Clin. 2001;51:15–36
  4. Harpole DH, Johnson CM, Wolfe WG, George SL, Seigler HF. Analysis of 945 cases of pulmonary metastatic melanoma. Thorac. Cardio. Surg. 1992;103:743–750
  5. Majeski J. Bilateral breast masses as initial presentation of widely metastatic melanoma. J. Surg. Oncol. 1999;72:175–177
  6. Fidler IJ. Critical determinants of metastasis. Semin. Cancer Biol. 2002;12:89–96
  7. Frank SJ, Meyers M. Interferon as adjuvant therapy for high risk melanoma. Melanoma Lett. 1995;13:1–4
  8. Mohr P, Wechenthal M, Hauschild A. Adjuvant therapy in melanoma. Onkologie. 2003;26:227–233
  9. Legha SS. The role of interferon alfa in the treatment of metastatatic melanoma. Semin. Oncol. 1997;24:S24–S31
  10. Richards JM. Sequential chemoimmunotherapy for metastatic melanoma. Semin. Oncol. 1991;18:91–95
  11. Håkansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B. On down-regulation of the immune response to metastatic malignant melanoma. Cancer Inmunol. Inmunother. 1999;48:253–262
  12. Lentini A, Autuoria F, Mattiolia P, Caragliab M, Abbruzzeseb A, Beninati S. Evaluation of the efficacy of potential antineoplastic drugs on tumour metastasis by a computer-assisted image analysis. Eur. J. Cancer. 2000;36:1572–1577
  13. Miner KM, Kawaguchi T, Uba GW, Nicolson GL. Clonal drift of cell surface, melanogenic and experimental metastatic properties of in vivo-selected brain meninges-colonizing murine B16 melanoma. Cancer Res. 1982;4:4631–4638
  14. Brunos KW, Nicolson GL. Selection of malignant melanoma variant cell lines for ovary colonization. J. Supramol. Struct. 1979;11:517–528
  15. Tao TW, Burger MM, Matter A, Vogel K. Liver-colonizing melanoma cells selected from B-16 melanoma. Int. J. Cancer. 1979;23:854–857
  16. Gath L, Nicolson GL, Dulski K. Organ specificity of metastatic tumor colonization is related to organ-selective growth properties of malignant cells. Int. J. Cancer. 1986;38:289–294
  17. Kakuta S, Tagawa Y, Shibata S, Nanno M, Iwakura Y. Inhibition of B16 melanoma experimental metastasis by interferon-γ through direct inhibition of cell proliferation and activation of antitumor host mechanisms. Inmunology. 2002;105:92–100
  18. Kikkawa H, Imafuku H, Tsukada H, Oku N. Possible of immune surveillance at the initial phase of metastasis produced by B16BL6 melanoma cells. Febs Lett. 2002;467:11–216
  19. Vicente V, Martínez C, Yáñez J, Alcaraz M, Canteras M. Melanoma metastásico pulmonar: efectos del etanol y de flavonoides. Rev. Esp. Patol. 2003;36:425–432
  20. Nakayama J, Urabe A, Toyofuku K, Taniguchi S, Hori Y. Suppression of murine melanoma growth with a combination of micowave hyperthermia and local injection of interleukin 2. Bri. J. Dermatol. 1994;130:717–724
  21. Zhang W, Wang Y, Hou Y. Effects of Chinese medical fungus water extract on tumor metastasis and some parameters of immune function. Int. Inmunopharmacol. 2004;4:461–468
  22. Kobayashi M, Kobayashi H, Pollard RB, Suzuki F. A pathogenic role of th2 cells and their cytokine products on pulmonary metastasis of murine B16 Melanoma. J. Immunol. 1998;160:5869–5873
  23. Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cells-mediated resistance against tumor cells. J. Immunol. 1990;145:4365–4370
  24. Eggermont AMM, Gore M. European approach to adjuvant therapy of intermediate and high-risk malignant melanoma. Sem. Oncol. 2002;29:382–388
  25. Sabel MS, Sondak VK. Pros and Cons of adjuvant Interferon in the treatment of melanoma. Oncologist. 2003;8:451–458
  26. Hansson J. Systemic therapy of malignant melanoma. Med. Oncol. 1997;14:73–81
  27. Bossserhoff AK, Echtenacher B, Hein R, Buettner R. Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res. 2001;11:417–421
  28. Fuzii HT, Travassos LR. Transiente resistance to B16F10 melanoma growth and metastasis in CD43 −/−mice. Melanoma Res. 2002;12:9–16
  29. Lentini A, Kleinman HK, Mattioli V, Autuori-Pezzoli V, Nicolini L, Pietrini A, et al. Inhibition of melanoma pulmonary metastasis by methylxanthines due to decreased invasión and proliferation. Melanoma Res. 1998;8:131–137
  30. Gutman H, Schachter J, Stopel E, Gutman R, Lahav J. Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy. Cancer. 2002;94:780–785
  31. Engelberg H. Actions of heparin that may affect the malignant process. Cancer. 1999;85:257–272
  32. Nieswandt B, Hafner M, Echtrncher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer. 1999;59:1295–1300
  33. Nierodzik ML, Kelpfish A, Karpatkin S. Role of platelets, thrombim, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Throm. Haemost. 1995;74:282–290
  34. Tedejarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, et al. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon α combined with paclitaxel. Clin. Cancer Res. 2002;8:2413–2422
  35. Sangfelt O, Erickson S, Grander D. Mechanisms of interferon-induced cell cycle arrest. Front. Biosci. 2000;5:D479–D487
  36. Maellaro E, Pacenti L, Del Bello B. Different effects of interferon-alpha on melanoma cell lines: a study on telomerase reverse transcriptase, telomerase activity and apoptosis. Br. J. Dermatol. 2003;148:1115–1124
  37. Grebenova D, Kuzelova K, Fuchs O, Halada P, Havlicek V, Marinov I, et al. Interferon-alpha suppresses proliferation of chronic myelogenous leukemia cells K562 by extending cell cycle S-phase without inducing apoptosis. Blood Cells Mol. Dis. 2004;32:262–269
  38. Håkansson A, Gustafsson B, Krysander L, Håkansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br. J. Cancer. 1996;74:670–676
  39. Håkansson A, Gustafsson B, Krysander L, Håkansson L. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J. Interferon Cytokine Res. 1998;18:33–39
  40. Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, et al. Mechanism of Interferon alfha on inhibition of Metastasis and Angiogenesis of hepatocellular Carcinoma after curative resection in nude mice. J. Gastrointest. Surg. 2003;7:587–594

PII: S0304-3835(04)00943-7

doi: 10.1016/j.canlet.2004.11.047

Cancer Letters
Volume 225, Issue 1 , Pages 75-83 , 8 July 2005

Article Tools

* Image Usage & Resolution